Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19

Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19

Since December 2019, a novel coronavirus (severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2)) infection has been rapidly spreading worldwide and causing the respiratory illness, coronavirus disease 2019 (COVID‐19). The antiretroviral drug favipiravir (FPV) has been experimentally used for...

Full description

Bibliographic Details
Main Authors:	Kei Irie, Atsushi Nakagawa, Hirotoshi Fujita, Ryo Tamura, Masaaki Eto, Hiroaki Ikesue, Nobuyuki Muroi, Keisuke Tomii, Tohru Hashida
Format:	Article
Language:	English
Published:	Wiley 2020-09-01
Series:	Clinical and Translational Science
Online Access:	https://doi.org/10.1111/cts.12827

Similar Items

Effectiveness of Pharmacist–Physician Collaborative Management for Patients With Idiopathic Pulmonary Fibrosis Receiving Pirfenidone
by: Yukari Satsuma, et al.
Published: (2020-11-01)

Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study
by: Kanae Yamashita, et al.
Published: (2021-07-01)

Polypharmacy-associated potential contraindications of drug prescriptions in patients with primary angle closure disease in a real-world setting
by: Fumiaki Tanaka, et al.
Published: (2021-05-01)

Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19
by: Michael G. Ison, et al.
Published: (2021-01-01)

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.
by: Thi Huyen Tram Nguyen, et al.
Published: (2017-02-01)

Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series
by: Kent Doi, et al.
Published: (2020-07-01)

Characterization of susceptibility variants of poliovirus grown in the presence of favipiravir
by: Tohru Daikoku, et al.
Published: (2018-10-01)

Effect of favipiravir and an anti-inflammatory strategy for COVID-19
by: Hitoshi Yamamura, et al.
Published: (2020-07-01)

Favipiravir in Therapy of Viral Infections
by: Ryta Łagocka, et al.
Published: (2021-01-01)

Novel Polymorph of Favipiravir—An Antiviral Medication
by: Alexander S. Goloveshkin, et al.
Published: (2021-01-01)

Role of favipiravir in the treatment of COVID-19
by: Shashank Joshi, et al.
Published: (2021-01-01)

Favipiravir: the hidden threat of mutagenic action
by: O. P. Zhirnov, et al.
Published: (2021-05-01)

Favipiravir Use in COVID-19 Treatment
by: Emre KARA, et al.
Published: (2021-03-01)

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
by: Rahmet Guner, et al.
Published: (2021-03-01)

Combination treatment of short-course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD
by: Hideki Inoue, et al.
Published: (2020-01-01)

Plasma concentration of amitriptyline and metabolites after resuscitation from cardiopulmonary arrest following an overdose: A case report
by: Motozumi Ando, et al.
Published: (2021-02-01)

The pharmacokinetics and pharmacodynamics of propofol in the critically ill child
by: Rigby-Jones, Ann Elizabeth
Published: (2005)

Antimicrobial pharmacokinetics and pharmacodynamics in critically ill patients
by: Lonsdale, Dagan Osborne
Published: (2018)

Maporal Hantavirus β-Integrin Utilization and Sensitivity to Favipiravir
by: Buys, Kristin K.
Published: (2010)

Therapeutic efficacy of favipiravir against Bourbon virus in mice.
by: Traci L Bricker, et al.
Published: (2019-06-01)

Advanced researches on the inhibition of influenza virus by Favipiravir and Baloxavir
by: Qiongqiong Fang, et al.
Published: (2020-06-01)

Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir.
by: Ana I de Ávila, et al.
Published: (2016-01-01)

Use of Favipiravir to Treat Lassa Virus Infection in Macaques
by: Kyle Rosenke, et al.
Published: (2018-09-01)

Antiviral Efficacy of Ribavirin and Favipiravir against Hantaan Virus
by: Jennifer Mayor, et al.
Published: (2021-06-01)

Snf1 AMPK positively regulates ER-phagy via expression control of Atg39 autophagy receptor in yeast ER stress response.
by: Tomoaki Mizuno, et al.
Published: (2020-09-01)

Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza
by: Yeming Wang, et al.
Published: (2020-12-01)

A case of pleural effusion caused by Mycobacterium fortuitum and Mycobacterium mageritense coinfection
by: Ryosuke Hirabayashi, et al.
Published: (2019-08-01)

Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis
by: D.V. Pérez Civantos, et al.
Published: (2019-09-01)

Amikacin Population Pharmacokinetics in Critically Ill Kuwaiti Patients
by: Kamal M. Matar, et al.
Published: (2013-01-01)

Population pharmacokinetics of meropenem in critically ill infant patients
by: Wanlika Yonwises, et al.
Published: (2021-10-01)

Interaction between warfarin and short-term intravenous amiodarone in intensive care unit patients after cardiac surgery
by: Tomoki Takase, et al.
Published: (2018-05-01)

Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis
by: Haruna Yamamoto, et al.
Published: (2018-07-01)

Favipiravir elicits antiviral mutagenesis during virus replication in vivo
by: Armando Arias, et al.
Published: (2014-10-01)

Favipiravir Experience in Covid-19 Positive Myasthenia Gravis Patients
by: Recep Yevgi, et al.
Published: (2021-06-01)

Favipiravir-resistant influenza A virus shows potential for transmission.
by: Daniel H Goldhill, et al.
Published: (2021-06-01)

Population Pharmacokinetics and Dose Optimization of Ganciclovir in Critically Ill Children
by: SiChan Li, et al.
Published: (2021-01-01)

CHANGES IN PHARMACOKINETIC PROPERTIES OF ANTIBACTERIAL DRUGS IN CRITICALLY ILL PATIENTS
by: Agnieszka Małgorzata Cios, et al.
Published: (2020-02-01)

Citrate Pharmacokinetics in Critically Ill Patients with Acute Kidney Injury.
by: Yin Zheng, et al.
Published: (2013-01-01)

Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir
by: Qi Peng, et al.
Published: (2021-02-01)

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
by: Qingxian Cai, et al.
Published: (2020-10-01)